| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG-Azide (MW 2000) contains an azide (N3) group that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing alkyne groups. The DSPE lipid moiety anchors into lipid bilayers, while the PEG spacer provides water solubility and biocompatibility.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG-Azide (MW 2000) is used to prepare nanoparticles or liposomes as targeted drug carriers. The azide group enables the conjugation of alkyne-functionalized targeting ligands, fluorescent probes, or therapeutic agents via CuAAC click chemistry.
|
| ln Vivo |
In vivo, DSPE-PEG-Azide (MW 2000)-containing nanoparticles can be used for targeted drug delivery. The PEG component reduces opsonization and prolongs circulation time, while the azide group enables the attachment of targeting moieties for specific delivery to tissues or cells of interest.
|
| Enzyme Assay |
Non-cellular assays for DSPE-PEG-Azide (MW 2000) typically involve demonstrating its ability to undergo click chemistry reactions. The compound can be incubated with an alkyne-functionalized molecule, and the formation of the conjugation product can be confirmed by techniques such as mass spectrometry or gel electrophoresis.
|
| Cell Assay |
In vitro cellular assays for DSPE-PEG-Azide (MW 2000) involve treating cells with DSPE-PEG-Azide-containing nanoparticles to assess their cellular uptake, targeting efficiency, and therapeutic efficacy. The compound itself is a linker and does not have direct biological activity on cells.
|
| Animal Protocol |
In vivo animal experiments for DSPE-PEG-Azide (MW 2000) would involve administering DSPE-PEG-Azide-containing nanoparticles to animal models to evaluate their biodistribution, pharmacokinetics, and therapeutic efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: DSPE-PEG-Azide (MW 2000)-containing nanoparticles exhibit prolonged circulation due to the PEG component. The pharmacokinetics are influenced by the size, surface properties, and targeting ligands of the nanoparticles. The azide group itself does not significantly affect the PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological profile: DSPE-PEG-Azide (MW 2000) is generally considered biocompatible and non-toxic at concentrations used in research applications. PEGylated lipids are well-tolerated, and the azide group is not known to be toxic. Standard safety precautions for handling lipid reagents apply.
|
| References |
[1]. Matthew R Warren , et al. Milk exosomes with enhanced mucus penetrability for oral delivery of siRNA. Biomater Sci. 2021 Jun 15;9(12):4260-4277.
|
| Additional Infomation |
DSPE-PEG-Azide (MW 2000) has an average molecular weight of 2000 and a purity of 98%+. It is an amphiphilic lipid-polymer conjugate used for click chemistry and drug delivery applications. It is supplied for research purposes only.
|
| Molecular Weight |
2000(Average)
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL
Ethanol :~1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
